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Background/aim: To evaluate the malignancy risk of thyroid nodules in different clinical thyroid diseases.
Materials and methods: Patients who underwent thyroidectomy between 2007 and 2014 were grouped as euthyroid, hypothyroid, and
hyperthyroid. Further classification was made depending on the presence of solitary/multiple thyroid nodules.
Results: Among 2870 patients, 1719 (59.9%) were euthyroid, 962 (33.5%) were hyperthyroid, and 189 (6.6%) were hypothyroid. Overall
malignancy was detected in 980 (34.1%) patients. Malignancy rates were 42.1%, 42.9%, and 18.3% in the euthyroid, hypothyroid, and
hyperthyroid groups, respectively (P < 0.001). A total 41.4% of patients with euthyroid nodular goiter (ENG) and 46.3% of patients with
euthyroid multinodular goiter (EMNG) had thyroid malignancy (P = 0.169). Mean tumor size and capsular and vascular invasion were
significantly lower in EMNG than in ENG. Among hypothyroid patients, 45.7% with solitary and 42.2% with multiple nodules were
malignant (P = 0.705). When toxic nodular goiter and toxic multinodular goiter were analyzed together, malignancy rate was 24.7%
(104/421), and when Graves with nodule/nodules was considered, it was 19.7% (59/299).
Conclusion: In hypothyroid or euthyroid patients who underwent thyroidectomy, malignancy rate was higher than 40%, and was
lower in hyperthyroid patients. Patients with multiple nodules carry a similar risk of malignancy as patients with solitary nodules,
independent of the functional status.
Key words: Thyroid cancer, thyroid functions, thyroid nodule

1. Introduction
Nodular thyroid diseases are the most frequent diseases of
the thyroid gland. Prevalence of clinically apparent thyroid
nodules is 5% in women and 1% in men living in iodinesufficient regions of the world. However, over the past
two decades, the widespread use of ultrasonography (US)
has resulted in a dramatic increase in thyroid nodules,
estimated at 19%–68% in the general population (1). The
high prevalence of thyroid nodules requires evidencebased rational strategies for their differential diagnosis, risk
stratification, treatment, and follow-up. These strategies
mainly concentrate on the risk of malignancy. Thyroid
carcinoma is the most frequent cancer of the endocrine
glands and constitutes 1% of human neoplasias. The yearly
incidence of thyroid cancer has nearly tripled from 4.9
per 100,000 to 14.3 per 100,000 in approximately 35 years
(2). Such incidence is higher if cases of occult carcinoma
are taken into account. Advanced age, male sex, radiation
exposure, rapidly growing mass in neck, >4 cm nodule,
* Correspondence: black_snowtr@yahoo.com

and a family history of thyroid cancer are the main risk
factors for malignant thyroid lesions (1,3).
Clinical thyroid diseases can be classified as euthyroid,
hypothyroid, and hyperthyroid, according to functional
status. Thyroid functions are normal in a considerable
amount of patients with thyroid cancer. Measurement
of high sensitive thyrotropin (TSH) in serum plays the
main role in the diagnosis of thyroid dysfunctions and
has a predictive value for thyroid malignancies. In a study
consisting of 1500 patients, prevalence of malignancy
was significantly lower in patients with serum TSH <
0.4 mU/L, compared to those with TSH > 0.4 mU/L (4).
Furthermore, the highest malignancy risk was shown in
patients with TSH levels higher than 5.5 mU/L. There
are a number of studies reporting an association between
increased malignancy and high serum TSH levels even in
normal ranges (5,6).
The term goiter refers to the abnormal growth of
the thyroid gland. Goiters can be diffuse or nodular,
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depending on the cause, and may be associated with
normal, decreased, or increased thyroid hormone
production. Additionally, absence or presence of a single
or multiple nodules determines the nodular status of the
thyroid disease. In contrast to studies suggesting higher
malignancy risk in solitary thyroid nodules (7,8), several
studies have shown that the risk is similar in patients with
multinodular disease and those with solitary nodules
(9,10).
In this study, we evaluated malignancy risk in
various clinical thyroid diseases classified according to
functional and morphological status. Additionally, we
compare histopathological features of malignant lesions
accompanying different thyroid diseases.
2. Materials and methods
The study was approved by the Clinical Investigations
Ethical Committee of the School of Medicine, Yıldırım
Beyazit University, Turkey (Chairperson: MD Halil Kara,
date: 21.10.2015, Protocol No. 210). Patients who had
undergone thyroidectomy in our center between 2007
and June 2014 were evaluated retrospectively in this study.
Patients with a previous history of thyroid surgery, or
percutaneous invasive procedure for thyroid nodule, or
radiotherapy to the head and neck region were excluded
from the study. According to the preoperative functional
status, patients were classified into 3 groups: euthyroid,
hypothyroid, and hyperthyroid. Demographic features,
serum TSH levels, presence of thyroid autoantibodies, and
use of medication for thyroid dysfunctions were obtained
from medical records. Chemiluminescent enzyme
immunoassay (Immulite 2000, Diagnostic Products Corp.
Los Angeles, CA, USA, and UniCel DXI 800, Beckman
Coulter, Brea, CA, USA) were used for measurement of
serum TSH, antithyroid peroxidase antibody (antiTPO),
and antithyroglobulin antibody (antiTGAb) levels. Normal
range for serum TSH was 0.4–4 μIU/mL. The thyroid
antibody levels over the upper range were accepted as
positive. Patients with a basal TSH level > 4.0 μIU/mL and
patients on levothyroxine therapy were defined as having
hypothyroidism. Euthyroidism was defined as normal TSH
values in the absence of thyroid medication. Patients with
TSH values < 0.4 μIU/mL or patients using antithyroid
medications were considered to have hyperthyroidism.
Preoperative thyroid US findings were reviewed from
medical records. Euthyroid and hypothyroid patients
were further classified according to the presence of
solitary or multiple nodules preoperatively. The causes of
hyperthyroidism were Graves disease, solitary autonomous
nodule, or multiple toxic nodules. The differential diagnosis
was made by US findings, 99mTc-pertechnatae scintigraphy,
131
I uptake results, and TSH receptor antibody levels.
Hyperthyroid patients were further classified according to
the presence and number of nodules.
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Eventually, 9 different clinical thyroid diseases were
defined: euthyroid nodular goiter (ENG), euthyroid
multinodular goiter (EMNG), hypothyroidism with
single nodule (hypothyroid + NG), hypothyroidism with
multiple nodules (hypothyroid + MNG), toxic nodular
goiter (TNG), toxic multinodular goiter (TMNG), Graves
without nodule (Graves), Graves with solitary nodule
(Graves + NG), and Graves with multiple nodule (Graves
+ MNG). No operation was performed on any euthyroid or
hypothyroid patient without nodule/nodules. Thus, there
was no group of diffuse goiter patients with euthyroidism
or hypothyroidism.
Operation indications were classified as giant nodule/
compression symptoms, thyrotoxicosis, nondiagnostic
cytology, indeterminate (atypia of undetermined
significance/follicular lesion of undetermined significance,
follicular neoplasm/suspicious for follicular neoplasm,
suspicious for malignancy) cytology and malignant
cytology results, suspicious US features (hypoechoic
texture, solid component, irregular margins, absence
of peripheral halo, presence of microcalcification, and
anteroposterior/transverse diameter > 1), and other
(including increase in nodule size, high nodule number
that makes clinical follow-up unfeasible, and coexistent
parathyroid adenoma).
Postoperative histopathological diagnosis and
malignancy rates were determined in each group. Nodular
hyperplasia, colloidal goiter, follicular adenoma, and
Hürthle cell adenoma were defined as benign thyroid
lesions. Thyroid cancer was classified as PTC, FTC,
Hürthle cell cancer, thyroid tumor of unknown malignant
potential (TT-UMP), medullary thyroid cancer, and
undifferentiated cancer. Tumoral characteristics (size,
capsular and vascular invasion, extrathyroidal extension,
and lymph node metastasis) were analyzed. A tumor was
defined as “incidental” when an unsuspected cancer was
identified incidentally during pathologic examination of
thyroid tissue removed for benign disease.
3. Results
Data of 2870 patients were analyzed, of which 2203
(76.8%) were female and 667 (23.2%) were male. There
were 227 (7.9%) patients in the ENG group, 1492 (52.0%)
in EMNG, 35 (1.2%) in hypothyroid + NG, 154 (5.4%) in
hypothyroid + MNG, 59 (2.1%) in TNG, 362 (12.6%) in
TMNG, 242 (8.4%) in Graves, 55 (1.9%) in Graves + NG,
and 244 (8.5%) in Graves + MNG groups.
When groups were organized according to functional
status, there were 1719 (59.9%) patients with euthyroidism,
189 (6.6%) with hypothyroidism, and 962 (33.5%)
with hyperthyroidism (Table 1). Mean age was similar
between groups and the female sex was predominant
in all groups. The ratio of female sex in the hypothyroid
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Table 1. Comparison of clinical features and histopathology results in patients with euthyroidism, hypothyroidism, and hyperthyroidism.
Euthyroid
n = 1719 (59.9%)

Hypothyroid
n = 189 (6.6%)

Hyperthyroid
n = 962 (33.5%)

P

Sex
Male
Female

343 (20.0%)
1376 (80.0%)b

16 (8.5%)
173 (91.5%)a,c

308 (32.0%)
654 (68.0%)

<0.001

Age (years)

49.09 ± 11.93

48.78 ± 12.37

49.38 ± 13.08

0.767

Thyrotrophin (μIU/mL)

1.46 ± 1.00

5.05 ± 6.72

0.98 ± 4.03

<0.001

AntiTPO positivity (n = 1836)

205 (18.4%)

76 (55.1%)

218 (37.4%)

<0.001

AntiTg positivity (n = 1831)

221 (20.0%)

54 (42.5%)

166 (27.8%)

<0.001

Operation indications
Giant nodule/compression symptoms
Thyrotoxicosis
Nondiagnostic cytology
Indeterminate cytology*
Malignant cytology
Suspicious ultrasonography features
Other
Unknown

628 (36.5%)
0 (0.0%)
179 (10.4%)
633 (36.8%)
137 (8.0%)
34 (2.0%)
77 (4.5%)
31 (1.8%)

21 (11.1%)
0 (0.0%)
23 (12.2%)
110 (58.2%)
21 (11.1%)
1 (0.5%)
9 (4.8%)
4 (2.1%)

224 (23.3%)
514 (53.4%)
50 (5.2%)
83 (8.6%)
13 (1.4%)
7 (0.7%)
7 (0.7%)
64 (6.7%)

Histopathology
Benign
Malignant

996 (57.9%)
723 (42.1%)

108 (57.1%)
81 (42.9%)

786 (81.7%)
176 (18.3%)b,c

<0.001

58/700 (8.3%)

11/80 (13.8%)c

8/171 (4.7%)

0.046

Lymph node metastasis (n = 951)

< 0.001

AntiTPO: antithyroid peroxidase, AntiTg: antithyroglobulin.
*Indeterminate cytology refers to ‘atypia of undetermined significance/follicular lesion of undetermined significance, follicular
neoplasm/suspicious for follicular neoplasm, suspicious for malignancy’.
a: P < 0.05 for euthyroid vs. hypothyroid.
b: P < 0.05 for euthyroid vs. hyperthyroid.
c: P < 0.05 for hypothyroid vs. hyperthyroid.

group was significantly higher compared to the euthyroid
and hyperthyroid groups (P < 0.001 each). The euthyroid
group had a higher ratio of female sex compared to the
hyperthyroid group (P < 0.001).
The most common surgical indications were
nondiagnostic/indeterminate/malignant cytology results
(55.2%) and giant nodule/compression symptoms
(36.5%) in euthyroid patients (Table 1). A total 81.5% of
hypothyroid patients were operated on for nondiagnostic/
indeterminate/malignant cytology results. Thyrotoxicosis
was the first (53.4%) and giant nodule/compression
symptoms (23.3%) were the second most common
operation indications in hyperthyroid patients.
Histopathologically, 980 (34.1%) patients had thyroid
malignancy and 1890 (65.9%) had benign thyroid disease.
Considering malignancy rate according to functional
status, 723 (42.1%) of euthyroid patients, 81 (42.9%) of
hypothyroid patients, and 176 (18.3%) of hyperthyroid
patients had malignant thyroid disease (Table 1).

Malignancy rate was significantly lower in the hyperthyroid
group compared to the euthyroid and hypothyroid groups
(P < 0.001 for each).
When the data of patients with thyroid cancer
were analyzed, 73.8% of patients with thyroid cancer
were euthyroid preoperatively, whereas 17.9% were
hyperthyroid and 8.3% were hypothyroid. Overall, there
were 1387 carcinoma foci in 980 malignant patients.
Among tumoral foci, 1051 (75.8%) were present in the
euthyroid group, 115 (8.3%) in the hypothyroid group,
and 221 (15.9%) were in the hyperthyroid group (Table
2). The distribution of tumor type was similar in all three
groups (P = 0.705). Tumor size was significantly higher in
the euthyroid group compared to the hyperthyroid group
(P = 0.002). There was no significant difference in terms of
tumor size between the euthyroid and hypothyroid groups
(P = 0.582), and hyperthyroid and hypothyroid groups (P
= 0.371).
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Table 2. Comparison of tumoral features of thyroid carcinoma foci in patients with euthyroidism, hypothyroidism, and hyperthyroidism.
Malignant foci
n = 1387

Euthyroid
n = 1051 (75.8%)

Hypothyroid
n = 115 (8.3%)

Hyperthyroid
n = 221 (15.9%)

Tumor type
Papillary
Follicular
Hürthle cell
TT-UMP
Medullary
Undifferentiated

979 (93.2%)
22 (2.1%)
15 (1.4%)
18 (1.7%)
12 (1.1%)
5 (0.5%)

109 (94.8)
1 (0.9%)
0
1 (0.9%)
2 (1.7%)
2 (1.7%)

205 (92.8%)
8 (3.6%)
1 (0.5%)
5 (2.3%)
1 (0.5%)
1 (0.5%)

Tumor size (mm)

11.16 ± 12.86b

9.98 ± 9.05

8.09 ± 10.07

0.003

Microcarcinoma

641 (61.0%)

68 (59.1%)

166 (75.1%)b,c

<0.001

Incidental

471 (44.8%)a

46 (40.0%)

147 (66.5%)b,c

<0.001

Capsular invasion

234 (22.3%)

28 (24.3%)

36 (16.3%)

0.419

Vascular invasion

46 (4.4%)

4 (3.5%)

5 (2.3%)

0.508

Extrathyroidal extension

102 (9.7%)

15 (13%)

20 (9%)

0.601

P

0.705

TT-UMP: Thyroid tumor of unknown malignant potential.
a: P < 0.05 for euthyroid vs. hypothyroid.
b: P < 0.05 for euthyroid vs. hyperthyroid.
c: P < 0.05 for hypothyroid vs. hyperthyroid.

Incidental thyroid cancer constituted 47.9% of all
malignant lesions. The highest rate of incidental thyroid
carcinoma was found in the hyperthyroid group followed
by the euthyroid and hypothyroid groups (66.5%, 44.8%,
and 40.0%, respectively, P < 0.001 for hyperthyroid vs.
euthyroid and hyperthyroid vs. hypothyroid, and P =
0. 004 for euthyroid vs. hypothyroid). Among 1387
carcinoma foci, 875 (63.1%) were microcarcinoma. The
rate of microcarcinoma was significantly higher in the
hyperthyroid group compared to the euthyroid and
hypothyroid groups (61.0% in the euthyroid, 59.1% in
the hypothyroid, and 75.1% in the hyperthyroid group,
respectively, P = 0.003 for hyperthyroid vs. euthyroid, and
P < 0.001 for hyperthyroid vs. hypothyroid). Capsular
invasion, vascular invasion, and extracapsular extension
were observed with similar rates in all groups. The only
significant difference was in lymph node metastasis, which
was higher in hypothyroid patients (13.8%) compared to
hyperthyroid patients (4.7%) (P = 0.011).
Subgroup analysis was made separately for euthyroid,
hypothyroid, and hyperthyroid patients. Among 1719
patients with euthyroidism, 227 (13.2%) had ENG and
1492 (86.8%) had EMNG (Table 3). Higher prevalence
was observed in females and mean age was higher in the
EMNG group compared to the ENG group (P < 0.001
each). Malignancy rates were 41.4% and 46.3% in ENG and
EMNG, respectively (P = 0.169). There was a statistically
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significant difference in tumor types between the two
groups (P < 0.001). PTC constituted 94.4% of tumors
in EMNG and 84.2% in ENG groups. A total 25.6% of
malignant lesions in ENG and 47.6% of malignant lesions
in EMNG were diagnosed incidentally (P < 0.001). Mean
tumor size, capsular invasion, and vascular invasion were
lower in the EMNG group (P < 0.001, P = 0.003, and P =
0.015, respectively).
There were 189 patients with hypothyroidism, of which
35 (18.5%) were in the hypothyroid + NG group and 154
(81.5%) were in the hypothyroid + MNG group (Table 4).
Sex distribution, mean age, and malignancy rates were
similar in the two groups. In the hypothyroid + NG group,
3 (17.6%) tumors were incidental, and in the hypothyroid
+ MNG group, 43 (43.9%) tumors were incidental (P =
0.042). Tumor size and all tumoral characteristics were
identical in the two groups.
There were 962 patients with hyperthyroidism (Table
5). Sex distribution was similar in all subgroups. Mean
age was significantly higher in TMNG (P < 0.05 for each)
and lower in Graves, compared to all other groups (P <
0.05 for each). Malignancy rates were similar in TNG,
TMNG, Graves + NG, and Graves + MNG groups, but
lower in Graves compared to the other groups (P < 0.01
for each). When TMNG and TNG were analyzed together,
malignancy rate was 24.7% (104/421), and when all
Graves patients with/without nodules were considered,
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Table 3. Comparison of demographical features, histopathology results, and tumoral characteristics in patients with euthyroid nodular
goiter and euthyroid multinodular goiter.
Euthyroid nodular goiter
n = 227 (13.2%)

Euthyroid multinodular goiter
n = 1492 (86.8%)

Sex
Male
Female

65 (28.6%)
162 (71.4%)

278 (18.6%)
1214 (81.4%)

<0.001

Age (years)

43.30 ± 12.51

49.97 ± 11.59

<0.001

Histopathology
Benign
Malignant

122 (53.7%)
105 (46.3%)

874 (58.6%)
618 (41.4%)

0.169

12/105 (11.4%)

46/595 (7.7%)

0.205

n = 133

n = 918

Tumor type
Papillary
Follicular
Hürthle cell
TT-UMP
Medullary
Undifferentiated

112 (84.2%)
5 (3.8%)
4 (3.0%)
4 (3.0%)
6 (4.5%)
2 (1.5%)

867 (94.4%)
17 (1.9%)
11 (1.2%)
14 (1.5%)
6 (0.7%)
3 (0.3%)

Tumor size (mm)

16.53 ± 15.53

10.38 ± 12.22

<0.001

Capsular invasion

39 (29.3%)

195 (21.2%)

0.003

Vascular invasion

11 (8.3%)

35 (3.8%)

0.015

Extrathyroidal extension

18 (13.5%)

84 (9.2%)

0.168

Incidental

34 (25.6%)

437 (47.6%)

<0.001

Lymph node metastasis (n = 700)
Malignant foci (n = 1051)

P

<0.001

TT-UMP: thyroid tumor of unknown malignant potential.

malignancy rate was 13.3% (72/541). Malignancy rate
increased to 19.7% when only Graves patients with
solitary and multiple nodules were considered. Tumor
type was significantly different between groups and this
difference was mostly related to the higher rate of FTC in
the TNG group. All 16 tumoral foci in Graves disease were
incidental, whereas rates of incidental tumors were similar
in other groups. There was a significant difference in terms
of tumor size between groups with the lowest size (3.53
± 2.52 mm) in the Graves group and the highest (14.67
± 16.40 mm) in the TNG group. Capsular invasion was
significantly higher in TNG compared to the other groups.
Vascular invasion, extrathyroidal extension, and lymph
node metastasis were observed with similar frequencies in
the groups.
4. Discussion
Approximately 7%–15% of all thyroid nodules are
malignant (1). The risk of malignancy in various clinical
thyroid disorders, such as Graves disease, toxic nodules,

Hashimoto thyroiditis (HT), and solitary/multiple nodules,
have been studied extensively in previous studies. However,
to the best of our knowledge, malignancy potential
under all these conditions had not been evaluated and
compared in the same study before. Here, we showed that
malignancy is detected at a higher prevalence in patients
with preoperative hypothyroidism and euthyroidism
compared to patients with hyperthyroidism. Nevertheless,
there was a 19.3%–24.9% malignancy rate in patients with
preoperative diagnosis of TNG, TMNG, and Graves with
solitary/multiple nodules. Presence of solitary or multiple
nodules did not change thyroid cancer risk in euthyroid,
hypothyroid, and hyperthyroid patients.
Increasing prevalence of thyroid cancer worldwide
is partly attributed to increased detection of subclinical
cancer resulting from advanced diagnostic techniques.
However, recent data suggest that improved surveillance
cannot be the only explanation for this; instead, several
environmental and habitual factors might contribute (11).
In total, we had a higher risk of malignancy (34.1%) than
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Table 4. Comparison of demographical features, histopathology results, and tumoral characteristics in patients with hypothyroid
nodular goiter and hypothyroid multinodular goiter.
Hypothyroid nodular goiter
n = 35 (18.5%)

Hypothyroid multinodular goiter
n = 154 (81.5%)

P

Sex
Male
Female

1 (2.9%)
34 (97.1%)

15 (9.7%)
139 (90.3%)

0.187

Age (years)

48.48 ± 11.57

48.84 ± 12.57

0.877

Histopathology
Benign
Malignant

19 (54.3%)
16 (45.7%)

89 (57.8%)
65 (42.2%)

0.705

1/16 (6.3%)

10/64 (15.6%)

0.330

n = 17

n = 98

Tumor type
Papillary
Follicular
Hürthle cell
TT-UMP
Medullary
Undifferentiated

16 (94.1%)
1 (5.9%)
0
0
0
0

93 (94.9%)
0
2 (2.0%)
1 (1.0%)
2 (2.0%)
0

Tumor size (mm)

12.29 ± 10.40

9.57 ± 8.79

0.256

Capsular invasion

5 (29.4%)

23 (23.5%)

0.598

Vascular invasion

0

4 (4.1%)

NA

Extrathyroidal extension

2 (11.8%)

13 (13.3%)

0.865

Incidental

3 (17.6%)

43 (43.9%)

0.042

Lymph node metastasis (n = 80)
Malignant foci (n = 115)

0.157

TT-UMP: thyroid tumor of unknown malignant potential.

generally expected for a thyroid nodule. In some studies
dealing with malignancy risk in thyroid nodules, fine
needle aspiration biopsy (FNAB) results were used as the
final diagnosis, and the risk was reported to range between
8% and 9.4% (5,12). When histopathological results are
taken into consideration, this risk increases to 13.7%–
37.6% in different series (6,13,14). Among 3629 patients
undergoing surgical treatment, 23.6% were diagnosed
with malignant nodules in a study by Lin et al. (15). A
possible cause of the high rate of malignancy in our study
might be incidental carcinomas and microcarcinomas,
which comprise 47.9% and 63.1% of all malignancies,
respectively. In addition, iodine deficiency is related to
hypertrophy of the thyroid gland and development of
nodular goiter. Turkey was a severely iodine-deficient
region, and mandatory salt iodination has been carried
out since 1999, which has brought our country to a
moderate iodine deficiency region. Thus, we commonly
come across nodular thyroid diseases in routine clinical
practice. Moreover, our center is a reference center, and
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many patients with nodular goiter and indeterminate or
malignant cytology are referred to our clinic for cytological
evaluation or thyroidectomy.
It has long been suggested that solitary thyroid
nodules carry a higher risk of malignancy compared to
MNG. In a study of 300 patients, 46.2% of solitary thyroid
nodules were malignant compared to 22.5% of MNG
(7,8). However, this was not the case in several other
studies, which reported no difference in cancer prevalence
between patients with solitary nodules and those with
MNG (9,10,16). Independent of thyroid functional status,
malignancy rates were similar in patients with MNG and
solitary nodules in our study, and we agree that MNG
should no longer be considered an indicator of probable
benign disease, and that all suspicious nodules, in addition
to dominant ones, deserve cytological evaluation.
It is suggested that patients with thyroid cancer are
mostly euthyroid (17). In accordance with this observation,
the majority (73.8%) of patients with thyroid cancer were
euthyroid in our study.
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Table 5. Comparison of demographical features, histopathology results, and tumoral characteristics in patients with different clinical
diagnosis of hyperthyroidism.
TNG
n = 59
(6.1%)

TMNG
n = 362
(37.6%)

Graves
n = 242
(25.2%)

Graves + NG
n = 55
(5.7%)

Graves + MNG
n = 244
(25.4%)

Sex
Male
Female

25 (42.4%)
34 (57.6%)

106 (29.3%)
256 (70.7%)

79 (32.6%)
163 (67.4%)

20 (36.4%)
35 (63.6%)

78 (32.0%)
166 (68.0%)

Age (years)

50.59 ± 13.02 55.07 ± 10.92 39.50 ± 10.46 45.27 ± 12.34 51.36 ± 12.77

<0001

Histopathology
Benign
Malignant

45 (76.3%)
14 (23.7%)

272 (75.1%)
90 (24.9%)

229 (94.6%)
13 (5.4%)

43 (78.2%) 12 197 (80.7%)
(21.8%)
47 (19.3%)

<0.001

1/14 (7.1%)

4/88 (4.5%)

0/13 (0.0%)

1/12 (8.3%)

2/44 (4.5%)

0.879

n = 15

n = 116

n = 16

n = 16

n = 58

Tumor type
Papillary
Follicular
Hürthle cell
TT-UMP
Medullary
Undifferentiated

11 (73.3%)
4 (26.7%)
0
0
0
0

107 (92.2%)
3 (2.6%)
0
4 (3.4%)
1 (0.9%)
1 (0.9%)

16 (100%)
0
0
0
0
0

15 (93.7%)
0
1 (6.3%)
0
0
0

56 (96.6%)
1 (1.7%)
0
1 (1.7%)
0
0

Tumor size (mm)

14.67 ± 16.40 8.32 ± 11.23

3.53 ± 2.52

6.02 ± 5.94

7.77 ± 6.53

0.032

Capsular invasion

7 (46.7%)

20 (17.2%)

0

1 (6.3%)

8 (13.8%)

0.048

Vascular invasion

0

3 (2.6%)

0

1 (6.3%)

1 (1.7%)

0.871

Extrathyroidal extension

2 (13.3%)

12 (10.3%)

0

1 (6.3%)

5 (8.6%)

0.676

Incidental

9 (60%)

78 (67.2%)

16 (100%)

11 (68.8%)

33 (56.9%)

0.028

Lymph node metastasis (n = 171)
Malignant foci (n = 221)

P

0.323

0.003

TNG: toxic nodular goiter, TMNG: toxic multinodular goiter, NG: nodular goiter, MNG: multinodular goiter, TT-UMP: thyroid tumor
of unknown malignant potential.
*Post-hoc analysis for all variables;
Sex distribution: P > 0.05 for all comparisons of subgroups.
Age: P < 0.05 for all comparisons except TNG vs. Graves + NG and TNG vs. Graves + MNG.
Histopathology: P < 0.001 for comparisons of TMNG vs. Graves, TNG vs. Graves, Graves vs. Graves + NG, and Graves vs. Graves +
MNG.
Lymph node metastasis: P > 0.05 or nonapplicable for all comparisons of subgroups.
Tumor type: P = 0.015 for TMNG vs. TNG, P = 0.027 for TNG vs. Graves, P = 0.003 for TNG vs. Graves + MNG.
Tumor size: P > 0.05 for all comparisons of subgroups except TNG vs. Graves (P = 0.017).
Capsular invasion: P = 0.002 for TNG vs. Graves, P = 0.010 for TNG vs. Graves + NG,
P = 0.018 for TNG vs. Graves + MNG.
Vascular invasion: P > 0.05 or nonapplicable for all comparisons of subgroups.
Extrathyroidal extension: P > 0.05 for all comparisons of subgroups.

There is growing evidence that serum TSH has a
predictor value for malignant thyroid nodules. This was
explained by the fact that TSH acts as a growth factor for
thyrocytes. In a study of 1870 patients without any thyroid
dysfunction, median TSH was found to be significantly
higher in DTC patients compared to patients with benign
pathology (18). Similar results indicating that TSH levels
are signiﬁcantly higher in PTC compared to benign thyroid

diseases were obtained by other studies (5,6,12,13,18,19).
In this study, we did not concentrate on the risk of thyroid
cancer according to serum TSH levels, but compared
malignancy risk in patients with normal and abnormal
thyroid functions. Hyperthyroidism was associated with
a lower risk of thyroid cancer than euthyroidism and
hypothyroidism. The protective role of low TSH, shown in
previous studies, might be one of the factors responsible
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for this finding. Nevertheless, it should be noted that
hyperthyroid patients were operated more frequently for
benign diseases such as Graves or toxic nodules, whereas
euthyroid and hypothyroid patients were operated on
more frequently with indications harboring higher
malignancy potential such as malignant, indeterminate,
or nondiagnostic cytology results and giant nodules. The
higher rate of incidental thyroid tumors and lower tumor
size in hyperthyroid patients support this hypothesis.
In our study, tumoral characteristics were similar in
all groups, although lymph node metastasis was higher in
hypothyroid patients compared to hyperthyroid patients.
A possible reason might be the higher prevalence of
incidental tumors in the hyperthyroid group. Moreover,
hypothyroid patients were operated more frequently for
indeterminate or malignant cytology results.
Age is an independent risk factor for the development
of thyroid nodules (20). In our study, the mean age of
patients with EMNG was higher compared to patients with
ENG. With regard to tumoral characteristics in patients
with EMNG and ENG, poor prognostic factors, such as
tumor size, vascular invasion, and capsular invasion, were
observed at a lower frequency in the EMNG group. This
was probably related to a higher incidence of incidental
thyroid cancer in this group of patients. We generally prefer
to perform US-guided FNAB in all nodules >1–1.5 cm
and <1 cm with suspicious US features. However, it seems
that, despite all efforts, small tumoral lesions might be
left undiagnosed preoperatively in patients with multiple
nodules. It is known that the majority of incidental thyroid
carcinomas are PTC (21). Higher rate of PTC in EMNG
might be attributed to the incidentality of nearly half the
malignant lesions in this group of patients.
Thyroid cancer was detected in 42.9% of hypothyroid
patients who underwent thyroidectomy in our study.
Although there are studies showing no association between
HT and malignant thyroid lesions (22), many others show
increased prevalence of thyroid cancer in these patients.
Prevalence of thyroid cancer was found to be significantly
higher in patients with HT than in patients without HT in
the metaanalysis by Singh et al. In another study, patients
with PTC had a significantly higher prevalence of HT
compared to patients with benign thyroid nodular disease
(18.8% vs. 7.2%) (23–26). Additionally, we have shown that
34.5% of 919 patients with PTC had histopathologically
confirmed HT in a previous study (25). The association
between thyroid cancer and HT was attributed to
elevated levels of TSH found in hypothyroid patients
with HT. We did not determine the underlying causes
of hypothyroidism; however, HT, as the leading cause of
hypothyroidism in many countries, was probably the most
common cause in hypothyroid patients in our study.
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Graves disease can affect all ages, but is most common
in people between 20 and 50 years of age. In contrast, the
most frequent cause of spontaneous hyperthyroidism
is TMNG in elderly patients. The mean age of patients
with Graves in the present study was significantly lower
compared to patients with toxic autonomous nodules.
We found that Graves patients were significantly younger
than Graves patients with a nodule or nodules. Similarly
to our finding, in a study by Kim et al., the mean age of
patients with nodular Graves disease was significantly
higher compared to Graves patients without nodule (26).
Additionally, the authors indicated that the age of the
patient was the only signiﬁcant variable predicting the
presence of both nodules and cancer in Graves patients. It
seems that increased tendency for development of thyroid
nodule with advancing age is also valid for Graves patients
(20,27).
Nodules associated with Graves disease have been
reported in various studies, with a prevalence ranging
from 12.8% to 36.6% (21,26,28,29). However, 55.3% of
all Graves patients in our study had nodule/nodules at a
higher rate than that reported in the literature. This can be
explained by the fact that we only included patients that
underwent thyroidectomy. It is probable that surgery was
indicated more commonly in Graves patients with nodule/
nodules compared to those without nodules, for whom
medical follow-up or radioactive iodine treatment are
other options.
There is much variability in the prevalence of
malignancy in hyperthyroid patients. It has been reported
to range between 0.5% and 16.6% in patients with Graves
disease, 2.5%–12% in patients with TNG, and 1.6%–16.0%
in patients with TMNG (4,30–34). The discrepancy in
thyroid cancer prevalence in hyperthyroidism has been
explained by differences in treatment strategies, surgical
approach, and extent of histopathological examination
of the removed thyroid tissue in different centers.
Additionally, genetic and environmental factors, such as
living in an endemic goiter region and variations in iodine
exposure, may have an effect on thyroid cancer rates. In
the present study, thyroid cancer in TMNG/TNG patients
was observed at a higher frequency compared to that
generally reported in the literature. Possible explanations
for the high overall prevalence of thyroid cancer in our
study are also valid for these patients. In addition, we
routinely evaluate nodules in hyperthyroid patients
whatever the cause—Graves or autonomously functioning
nodule—with FNAB (when euthyroidism is achieved),
according to the indications identical to the ones used
for nodular goiter. This might have contributed to the
detection of cytologically suspicious nodules and increased
thyroidectomy decisions, instead of following patients with
long-term medical or radioactive iodine therapy. Secondly,
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when surgery is indicated in a patient with hyperthyroidism
in our center, total/near total thyroidectomy is preferred
instead of lobectomy/hemithyroidectomy. This approach
might be a factor that causes a high rate of incidental
thyroid cancer in hyperthyroid patients.
Considering all 541 Graves patients in our study,
malignancy was detected in 72 patients at a rate of 13.3%.
This was nearly the same as the study by Ren et al., who
showed a malignancy rate of 13.7% in surgically treated
Graves disease patients (35). It was reported that when
a thyroid nodule was present in Graves, the possibility
of finding a carcinoma was 22.2%, whereas it was only
2.9% when the disease was without a nodule (36). In a
multicentric study of 557 patients that had undergone
thyroidectomy for Graves disease, the incidence of thyroid
carcinoma was 3.8%, whereas this incidence was 15% if
patients with a nodule were considered (37). In our study,
prevalence of thyroid cancer in Graves, Graves + NG, and
Graves + MNG groups was consistent with these studies
(5.4%, 21.8%, and 19.3%, respectively). These findings
suggest that nodules in Graves should be managed in the
same way as any other thyroid nodule, including followup and consideration of a FNAB to exclude malignancy.
There are conflicting results with regard to aggressiveness
of thyroid cancer in Graves disease. Increased incidence
of aggressive features and locally advanced cancers in
these patients were reported in some studies (26,36,37).
However, discordant results were obtained by other
studies showing similar rates of multifocality, lymph node
metastasis, distant metastatis, and mortality of thyroid
cancer in patients with Graves disease and EMNG (38,39).
PTC constituted more than 90% of all tumor types in
all subgroups of hyperthyroidism, except TNG, in which
4 of 15 (26.7%) tumoral foci were FTC. In a metaanalysis
of solitary hyperfunctioning thyroid nodules harboring
thyroid carcinoma, FTC and Hürthle cell carcinoma
comprised 36.4% and 7.8% of 76 cases, respectively (40).
These rates were much higher than those defined in
guidelines for nodular thyroid diseases. No explanation
for the high ratio of FTC in such nodules exists to date;
however, the authors suggested that cytological diagnosis
of follicular neoplasm within a hot nodule may not be as
innocuous as previously thought.
In the present study, histopathological characteristics
such as vascular invasion, extrathyroidal extension, and
lymph node metastasis were similar in subgroups of
hyperthyroidism. Exceptionally, capsular invasion was
significantly higher in the TNG group compared to others,
which can be attributed to a higher rate of FTC in this
group. Nevertheless, the number of carcinomas in TNG
in this study is not sufficient to conclude that FTC and
capsular invasion are seen more frequently in this group
of patients.

The main strength of our study is its high number
of patients. In addition, to the best of our knowledge,
malignancy risk in such a diversity of clinical thyroid
diseases was evaluated and compared for the first time in
the literature. However, the most significant limitations
of our study were its retrospective design and possible
selection bias before thyroidectomy. Furthermore, we did
not perform further analyses considering the causes of
hypothyroidism. Moreover, there might be HT patients
with normal thyroid functions included in the euthyroid
group. Since the association between HT and thyroid
cancer—particularly DTC—was shown previously,
the rate of malignancy in the euthyroid group might
have been affected by euthyroid HT patients. Another
limitation was that we did not analyze scintigraphy
results and match hypoactive/hyperactive nodules with
malignant nodules in the histopathological examination
of hyperthyroid patients. Therefore, it was not possible to
determine whether the malignant foci originated from the
hyperactive nodule itself or from outside the hot nodule in
patients with TMNG/TNG.
In conclusion, although hyperthyroidism has long been
suggested to be a protective factor against thyroid cancer,
there are growing data contradicting this suggestion. We
showed lower prevalence of thyroid cancer in hyperthyroid
patients compared to euthyroid and hypothyroid patients,
yet the risk was still 18.3% in these patients, increasing to
19.7% when Graves patients without nodule were excluded.
Nearly half of the thyroid carcinomas were incidental.
Although the clinical significance of incidental thyroid
cancer is controversial, we think that when surgery is
indicated for some reason, total/near total thyroidectomy
may be a reasonable approach in many patients for
avoiding surgical risks of a completion thyroidectomy.
Additionally, multinodularity in a thyroid gland carries a
similar risk of malignancy as with solitary thyroid nodules,
independent of functional status, and the risk exceeds 40%
in both euthyroid and hypothyroid patients operated for
various reasons.
In conclusion:
1) Thyroid cancer was detected less frequently in
hyperthyroid patients compared to hypothyroid and
euthyroid patients.
2) The rate of thyroid malignancy in hyperthyroid
patients, operated for various indications, was 18.3%,
which might legitimize total/near total thyroidectomy
when surgery is planned.
3) Solitary nodule and multinodular goiter carried a
similar risk of thyroid malignancy.

1517

DİRİKOÇ et al. / Turk J Med Sci
References
1.

Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel
SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM et al.
American Thyroid Association Management guidelines for
adult patients with thyroid nodules and differentiated thyroid
cancer. Thyroid 2016; 26: 1-133.

2.

Davies L, Welch HG. Current thyroid cancer trends in the
United States. JAMA Otolaryngol Head Neck Surg 2014; 140:
317-322.

3.

Hegedus L. Clinical practice. The thyroid nodule. N Engl J Med
2004; 351: 1764-1771.

4.

Gelmini R, Franzoni C, Pavesi E, Cabry F, Saviano M.
Incidental thyroid carcinoma (ITC): a retrospective study in a
series of 737 patients treated for benign disease. Ann Ital Chir
2010; 81: 421-427.

5.

Polyzos SA, Kita M, Efstathiadou Z, Poulakos P, Slavakis A,
Sofianou D, Flaris N, Leontsini M, Kourtis A, Avramidis A.
Serum thyrotropin concentration as a biochemical predictor
of thyroid malignancy in patients presenting with thyroid
nodules. J Cancer Res Clin Oncol 2008; 134: 953-960.

6.

Haymart MR, Repplinger DJ, Leverson GE, Elson DF, Sippel
RS, Jaume JC, Chen H. Higher serum thyroid stimulating
hormone level in thyroid nodule patients is associated with
greater risks of differentiated thyroid cancer and advanced
tumor stage. Clin Endocrinol Metab 2008; 93: 809-814.

7.

Rago T, Fiore E, Scutari M, Santini F, Di Coscio G, Romani R.
Male sex, single nodularity, and young age are associated with
the risk of finding a papillary thyroid cancer on fine-needle
aspiration cytology in a large series of patients with nodular
thyroid disease. Eur J Endocrinol 2010; 162: 763-770.

8.

Jena A, Patnayak R, Prakash J, Sachan A, Suresh V,
Lakshmi AY. Malignancy in solitary thyroid nodule: a
clinicoradiopathological evaluation. Indian J Endocrinol
Metab 2015; 19: 498-503.

9.

Papini E, Guglielmi R, Bianchini A, Crescenzi A, Taccogna S,
Nardi F, Panunzi C, Rinaldi R, Toscano V, Pacella CM. Risk of
malignancy in nonpalpable thyroid nodules: predictive value
of ultrasound and color-Doppler features. J Clin Endocrinol
Metab 2002; 87: 1941-1946.

10.

11.

12.

Belfiore A, La Rosa GL, La Porta GA, Giuffrida D, Milazzo G,
Lupo L, Regalbuto C, Vigneri R. Cancer risk in patients with
cold thyroid nodules: relevance of iodine intake, sex, age and
multinodularity. Am J Med 1992; 93: 363-369.
Balasubramaniam S, Ron E, Gridley G, Schneider AB, Brenner
AV. Association between benign thyroid and endocrine
disorders and subsequent risk of thyroid cancer among 4.5
million U.S. male veterans. See comment in PubMed Commons
belowJ Clin Endocrinol Metab 2012; 97: 2661-2669.
Boelaert K, Horacek J, Holder RL, Watkinson JC, Sheppard
MC, Franklyn JA. Serum thyrotropin concentration as a novel
predictor of malignancy in thyroid nodules investigated by
fine-needle aspiration. J Clin Endocrinol Metab 2006; 91:
4295-4301.

1518

13.

Gul K, Ozdemir D, Dirikoc A, Oguz A, Tuzun D, Baser H,
Ersoy R, Cakir B. Are endogenously lower serum thyroid
hormones new predictors for thyroid malignancy in addition
to higher serum thyrotropin? Endocrine 2010; 37: 253-260.

14.

Gandolfi PP, Frisina A, Raffa M, Renda F, Rocchetti O, Ruggeri
C, Tombolini A. The incidence of thyroid carcinoma in
multinodular goiter: retrospective analysis. Acta Biomed 2004;
75: 114-117.

15.

Lin JD, Chao TC, Huang BY, Chen ST, Chang HY, Hsueh
C. Thyroid cancer in the thyroid nodules evaluated by
ultrasonography and fine-needle aspiration cytology. Thyroid
2005; 15: 708-717.

16.

McCall A, Jarosz H, Lawrence AM, Paloyan E. The incidence of
thyroid carcinoma in solitary cold nodules and in multinodular
goiters. Surgery 1986; 100: 1128-1132.

17.

Smith D, Thompson AM. Breast and endocrine surgery. In:
Lavelle-Jones M, Dent JA, editors. Surgery. Toronto, ON,
Canada: Elsevier, 2008. p. 119-141.

18.

Shi L, Li Y, Guan H, Li C, Shi L, Shan Z, Teng W. Usefulness of
serum thyrotropin for risk prediction of differentiated thyroid
cancers does not apply to microcarcinomas: results of 1,870
Chinese patients with thyroid nodules. Endocr J 2012; 59: 973980.

19.

Fiore E, Vitti P. Serum TSH and risk of papillary thyroid cancer
in nodular thyroid disease. J Clin Endocrinol Metab 2012; 97:
1134-1145.

20.

Gupta KL. Neoplasm of the thyroid gland. Clin Geriatr Med
1995; 11: 271-290.

21.

Miccoli P, Minuto MN, Galleri D, D’Agostino J, Basolo F,
Antonangeli L, Aghini-Lombardi F, Berti P. Incidental thyroid
carcinoma in a large series of consecutive patients operated on
for benign thyroid disease. ANZ J Surg 2006; 76: 123-126.

22.

Anil C, Goksel S, Gursoy A. Hashimoto’s thyroiditis is not
associated with increased risk of thyroid cancer in patients with
thyroid nodules: a single-center prospective study. Thyroid
2010; 20: 601-606.

23.

Singh B, Shaha AR, Trivedi H, Carew JF, Poluri A, Shah JP.
Coexistent Hashimoto’s thyroiditis with papillary thyroid
carcinoma: impact on presentation, management, and
outcome. Surgery 1999; 126: 1070-1076.

24.

Lun Y, Wu X, Xia Q, Han Y, Zhang X, Liu Z, Wang F, Duan
Z, Xin S, Zhang J. Hashimoto’s thyroiditis as a risk factor
of papillary thyroid cancer may improve cancer prognosis.
Otolaryngol Head Neck Surg 2013; 148: 396-402.

25.

Baser H, Ozdemir D, Cuhaci N, Aydin C, Ersoy R,
Kilicarslan A, Cakir B. Hashimoto’s thyroiditis does not affect
ultrasonographical, cytological, and histopathological features
in patients with papillary thyroid carcinoma. Endocr Pathol
2015; 26: 356-364.

DİRİKOÇ et al. / Turk J Med Sci
26.

Kim WB, Han SM, Kim TY, Nam-Goong IS, Gong G, Lee
HK, Hong SJ, Shong YK. Ultrasonographic screening for
detection of thyroid cancer in patients with Graves’ disease.
Clin Endocrinol 2004; 60: 719-725.

34.

Gul K, Di Ri Koc A, Ki Yak G, Ersoy PE, Ugras NS, Ozdemir
D, Ersoy R, Cakir B. Thyroid carcinoma risk in patients
with hyperthyroidism and role of preoperative cytology in
diagnosis. Minerva Endocrinol 2009; 34: 281-288.

27.

Faggiano A, Del Prete M, Marciello F, Marotta V, Ramundo
V, Colao A. Thyroid diseases in elderly. Minerva Endocrinol
2011; 36: 211-231.

35.

Ren M, Wu MC, Shang CZ, Wang XY, Zhang JL, Cheng H, Xu
MT, Yan L. Predictive factors of thyroid cancer in patients with
Graves’ disease. World J Surg 2014; 38: 80-87.

28.

Carnell NE, Valente WA. Thyroid nodules in Graves’ disease:
classification, characterization, and response to treatment.
Thyroid 1998; 8: 647-652.

36.

29.

Mishra A, Mishra SK. Thyroid nodules in Graves’ disease:
implications in an endemically iodine deficient area. J Postgrad
Med 2001; 47: 244-247.

Pacini F, Elisei R, Di Coscio GC, Anelli S, Macchia E, Concetti
R, Miccoli P, Arganini M, Pinchera A. Thyroid carcinoma in
thyrotoxicosis patients treated by surgery. J Endocrinol Invest
1988; 11: 107-112.

37.

30.

Kang AS, Grant CS, Thompson GB, van Heerden JA. Current
treatment of nodular goiter with hyperthyroidism (Plummer’s
disease): surgery versus radioiodine. Surgery 2002; 132: 916923.

Cappelli C, Braga M, De Martino E, Castellano M, Gandossi
E, Agosti B, Cumetti D, Pirola I, Mattanza C, Cherubini L et
al. Outcome of patients surgically treated for various forms of
hyperthyroidism with differentiated thyroid cancer: experience
at an endocrine center in Italy. Surg Today 2006; 36: 125-130.

38.

Edmonds CJ, Tellez M. Hyperthyroidism and thyroid cancer.
Clin Endocrinol (Oxf) 1998; 28: 253-259.

39.

Yano Y, Shibuya H, Kitagawa W, Nagahama M, Sugino K,
Ito K, Ito K. Recent outcome of Graves’ disease patients with
papillary thyroid cancer. Eur J Endocrinol 2007; 157: 325-329.

40.

Belfiore A, Garofalo MR, Giuffrida D, Runello F, Filetti S,
Fiumara A. Increased aggressiveness of thyroid cancer in
patients with Graves’ disease. J Clin Endocrinol Metab 1990;
70: 830-835.

31.

Negro R, Valcavi R, Toulis KA. Incidental thyroid cancer in
toxic and nontoxic goiter: is TSH associated with malignancy
rate? Results of a meta-analysis. Endocr Pract 2013; 19: 212218.

32.

Preece J, Grodski S, Yeung M, Bailey M, Serpell J. Thyrotoxicosis
does not protect against incidental papillary thyroid cancer.
Surgery 2014; 156: 1153-1156.

33.

Pazaitou-Panayiotou K, Michalakis K, Paschke R. Thyroid
cancer in patients with hyperthyroidism. Horm Metab Res
2012; 44: 255-262.

1519

